# Annexon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/annexon

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.annexonbio.com/
- Total disclosed funding: $225M
- Latest round: Series D (Jun 30, 2020)
- Investors on record: 16

## About

Based in San Francisco, California, and founded in 2007 by co-founders Ben Barres, Ph.D., and Arnon Rosenthal, Ph.D., Annexon, Inc. is a provider of complement-targeted therapies to patients suffering from autoimmune, neurodegenerative, and ophthalmic diseases, focusing on blocking the classical complement pathway. In June 2024, Annexon, Inc. raised USD 125 million in a private placement, selling 27.29 million shares at USD 4.58 apiece on the Nasdaq Global Select Market. In addition, underwriters were granted a 30-day option to purchase up to 18.750 million shares. The firm trades on NASDAQ under the ticker symbol ANNX. As of 2024, the company is led by its CEO, Douglas Love, JD.

The company provides a wide range of therapeutic solutions targeting the classical complement pathway. The firm's key offerings include the C1q-blocking antibody ANX005 for Guillain-Barré syndrome and ANX007 for other complement-mediated diseases.

## Funding rounds

- Series D, Jun 30, 2020, $102M — Blackstone Group, New Enterprise Associates, Bain Capital, Adage Capital Management, Surveyor Capital, BlackRock, Redmile Group, Deerfield Management, Alerce Investment Management, Farallon Capital Management, Janus Henderson Investors, Eventide Asset Management, Logos Capital
- Series C, Dec 7, 2018, $45M — Blackstone Group, New Enterprise Associates, Bain Capital, Novartis Venture Fund, Clarus Ventures, Adage Capital Management, Surveyor Capital, Alerce Investment Management
- Series B, Jun 23, 2016, $44M — New Enterprise Associates, Novartis Venture Fund, Clarus Ventures, Correlation Ventures, Alerce Investment Management
- Series A, Dec 15, 2014, $34M — Novartis Venture Fund, Clarus Ventures, Alerce Investment Management

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B, Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B, Series C
- Alerce Investment Management — Series A, Series B, Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series B
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series C, Series D
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C, Series D
- Adage Capital Management — Series C, Series D
- Surveyor Capital — Series C, Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series D
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D
- Janus Henderson Investors — Series D
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series D
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series D